The differential regulation of human telomerase reverse transcriptase and vascular endothelial growth factor may contribute to the clinically more aggressive behavior of p63-positive breast carcinomas

International Journal of Biological Markers

Volumn 20, Issue 4, 2005, Pages 227-234

  Ribeiro Silva, Alfredo ^a   Becker de Moura, H ^a   Ribeiro do Vale, F ^a   Zucoloto, S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast; Carcinoma; Human telomerase reverse transcriptase; Immunohistochemistry; p63; Tissue inhibitor of matrix metalloproteinase 1; Vascular endothelial growth factor

Indexed keywords

PROTEIN P63; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TUMOR MARKER; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR VASCULARIZATION;

EID: 30844437035     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.1177/172460080502000405     Document Type: Article

References (56)

1. Osada M, Ohba M, Kawahara C, et al. Cloning and functional analysis of human p51, which structurally and functionally resembles p53. Nat Med 1998; 4: 839-43.
2. Trink B, Okami K, Wu L, Sriuranpong V, Jen J, Sidransky D. A new human p53 homologue. Nat Med 1998; 4: 747-8.
3. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell 1998; 2: 305-16.
4. Westfall MD, Pietenpol JA. p63: Molecular complexity in development and cancer. Carcinogenesis 2004; 25: 857-64.
5. Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. P63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999; 398: 708-13.
6. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999; 398: 714-8.
7. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res 2002; 8: 494-501.
8. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol 2000; 157: 1769-75.
9. Barbareschi M, Pecciarini L, Cangi MG, et al. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Am J Surg Pathol 2001; 25: 1054-60.
10. Batistatou A, Stefanou D, Arkoumani E, Agnantis NJ. The usefulness of p63 as a marker of breast myoepithelial cells. In Vivo 2003; 17: 573-6.
11. Reis-Filho JS, Schmitt FC. Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker. Adv Anat Pathol 2002; 9: 280-9.
12. Reis-Filho JS, Milanezi F, Amendoeira I, Albergaria A, Schmitt FC. Distribution of p63, a novel myoepithelial marker, in fine-needle aspiration biopsies of the breast: an analysis of 82 samples. Cancer 2003; 99: 172-9.
13. Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, Schmitt FC. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch 2003; 443: 122-32.
14. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. The relationship between p63 and p53 expression in normal and neoplastic breast tissue. Arch Pathol Lab Med 2003; 127: 336-40.
15. Ribeiro-Silva A, Ramalho LNZ, Garcia SB, Zucoloto S. Is p63 reliable in detecting microinvasion in ductal carcinoma in situ of the breast? Pathol Oncol Res 2003; 9: 20-3.
16. Stefanou D, Batistatou A, Nonni A, Arkoumani E, Agnantis NJ. p63 expression in benign and malignant breast lesions. Histol Histopathol 2004; 19: 465-71.
17. Wang X, Mori I, Tang W, et al. p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer 2002; 9: 216-9.
18. Rieger PT. The biology of cancer genetics. Semin Oncol Nurs 2004; 20: 145-54.
19. Bloom HJG, Richardson WW. Histological grading and prognosis in breast cancer: a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 1957; 11: 359-77.
20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991; 19: 403-10.
21. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 966-78.
22. Abd El-Rehim DM, Pinder SE, Paish CE, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91: 1532-42.
23. Ikeda S, Shibata T, Eishi Y, Takizawa T, Koike M. Correlation between the expression of telomerase reverse transcriptase and proliferative activity in breast cancer cells using an immunocytochemical restaining method. Pathol Int 2003; 53: 762-8.
24. Lebeau A, Unholzer A, Amann G, et al. EGFR, HER-2/neu, cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 2003; 79: 187-98.
25. Singh M, Parnes MB, Spoelstra N, Bleile MJ, Robinson WA. p16 expression in sentinel nodes with metastatic breast carcinoma: evaluation of its role in developing triaging strategies for axillary node dissection and a marker of poor prognosis. Hum Pathol 2004; 35: 1524-30.
26. Sirvent JJ, Aguilar MC, Olona M, Pelegri A, Blazquez S, Gutierrez C. Prognostic value of apoptosis in breast cancer (pT1 -pT2). A TUNEL, p53, bcl-2, bag-1 and Bax immunohistochemical study. Histol Histopathol 2004; 19: 759-70.
27. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Overexpression of cyclinD1 predicts for poor prognosis in estrogen receptor-negative breast cancer patients. Int J Cancer 2002; 98: 415-8.
28. Wang-Rodriguez J, Urquidi V, Rivard A, Goodison S. Elevated osteopontin and thrombospondin expression identifies malignant human breast carcinoma but is not indicative of metastatic status. Breast Cancer Res 2003; 5: R136-43.
29. Ludovini V, Sidoni A, Pistola L, et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res Treat 2003; 81: 159-68.
30. Barnes A, Pinder SE, Bell JA, et al. Expression of p27kip1 in breast cancer and its prognostic significance. J Pathol 2003; 201: 451-9.
31. Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002; 118: 408-17.
32. Milde-Langosch K, Bamberger AM, Methner C, Rieck G, Loning T. Expression of cell cycle-regulatory proteins rb, p16/MTS1, p27/KIP1, p21/WAF1, cyclin D1 and cyclin E in breast cancer: correlations with expression of activating protein-1 family members. Int J Cancer 2000; 87: 468-72.
33. Baker EA, Stephenson TJ, Reed MW, Brown NJ. Expression of proteinases and inhibitors in human breast cancer progression and survival. Mol Pathol 2002; 55: 300-4.
34. Au NH, Gown AM, Cheang M, et al. p63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl Immunohistochem Mol Morphol 2004; 12: 240-7.
35. Burstein DE, Nagi C, Wang BY, Unger P. Immunohistochemical detection of p53 homolog p63 in solid cell nests, papillary thyroid carcinoma, and Hashimoto's thyroiditis: A stem cell hypothesis of papillary carcinoma oncogenesis. Hum Pathol 2004; 35: 465-73.
36. Gwosdz C, Balz V, Scheckenbach K, Bier H. p53, p63 and p73 expression in squamous cell carcinomas of the head and neck and their response to cisplatin exposure. Adv Otorhinolaryngol 2005; 62: 58-71.
37. Hara T, Kijima H, Yamamoto S, et al. Ubiquitous p63 expression in human esophageal squamous cell carcinoma. Int J Mol Med 2004; 14: 169-73.
38. Hu WF, Liu MQ, Zhao Q. Expression of p53, p63, and c-erbB-2 in endometrioid adenocarcinoma and their clinico-pathological significance. Ai Zheng 2004; 23: 1021-5.
39. Ivan D, Hafeez Diwan A, Prieto VG. Expression of p63 in primary cutaneous adnexal neoplasms and adenocarcinoma metastatic to the skin. Mod Pathol 2005; 18: 137-42.
40. Yu YW, Garber ME, Schluns K, Pacyna-Gengelbach M, Petersen I. Evaluation of p63 expression in lung cancer by use of complementary DNA and tissue microarray. Zhonghua Bing Li Xue Za Zhi 2004; 33: 324-7.
41. Zigeuner R, Tsybrovskyy O, Ratschek M, Rehak P, Lipsky K, Langner C. Prognostic impact of p63 and p53 expression in upper urinary tract transitional cell carcinoma. Urology 2004; 63: 1079-83.
42. Koker MM, Kleer CG. p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004; 28: 1506-12.
43. van Steensel B, Smogorzewska A, de Lange T. TRF2 protects human telomeres from end-to-end fusions. Cell 1998; 92: 401-13.
44. Niiyama H, Mizumoto K, Sato N, et al. Quantitative analysis of hTERT mRNA expression in colorectal cancer. Am J Gastroenterol 2001; 96: 1895-900.
45. Kumaki F, Kawai T, Churg A, et al. Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas. Am J Surg Pathol 2002; 26: 365-70.
46. Bieche I, Nogues C, Paradis V, et al. Quantitation of hTERT gene expression in sporadic breast tumors with a real-time reverse transcription-polymerase chain reaction assay. Clin Cancer Res 2000; 6: 452-9.
47. Poremba C, Heine B, Diallo R, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol 2002; 198: 181-9.
48. Mokbel K, Parris CN, Ghilchik M, Williams G, Newbold RF. The association between telomerase, histopathological parameters, and KI-67 expression in breast cancer. Am J Surg 1999; 178: 69-72.
49. Maisse C, Guerrieri P, Melino G. p73 and p63 protein stability: the way to regulate function? Biochem Pharmacol 2003; 66: 1555-61.
50. Townsend PA, Cutress RI, Sharp A, Brimmell M, Packham G. BAG-1: a multifunctional regulator of cell growth and survival. Biochim Biophys Acta 2003; 1603: 83-98.
51. Schimmer AD. Inhibitor of apoptosis proteins: translating basic knowledge into clinical practice. Cancer Res 2004; 64: 7183-90.
52. Zhang HG, Wang J, Yang X, Hsu HC, Mountz JD. Regulation of apoptosis proteins in cancer cells by ubiquitin. Oncogene 2004; 23: 2009-15.
53. Davidson B, Reich R, Risberg B, et al. The biological role and regulation of matrix metalloproteinases (MMP) in cancer. Arkh Patol 2002; 64: 47-53.
54. Tang Y, Nakada MT, Kesavan P, et al. Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 2005; 65: 3193-9.
55. Noel A, Maillard C, Rocks N, et al. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004; 57: 577-84.
56. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.